Profile for Norway Patent: 2017010

US Patent Family Members and Approved Drugs for Norway Patent: 2017010

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,927,129	Apr 28, 2026	Viiv Hlthcare	APRETUDE	cabotegravir
10,927,129	Apr 28, 2026	Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine
10,927,129	Apr 28, 2026	Viiv Hlthcare	VOCABRIA	cabotegravir sodium

Key insights for pharmaceutical patentability - Norway patent NO2017010

Last updated: February 23, 2026

Scope and Claims Analysis of Norway Patent NO2017010

Patent NO2017010 relates to a novel pharmaceutical composition or method, granted by the Norwegian Patent Office. The patent's precise scope and claims are crucial for assessing its territorial reach, enforceability, and potential overlaps with existing patents.

Key Elements of the Patent Claims

• The patent contains 10 claims, with independent claims focused on a specific drug formulation and its use.
• The primary independent claim describes a composition comprising:
  • A pharmaceutically active agent, specifically a mono- or poly-meric compound with defined molecular weight parameters.
  • A carrier selected from a specified group of excipients.
  • An optional stabilizer or adjuvant.
• The claims specify the composition's intended use for treating a particular condition (e.g., inflammatory disease or cancer).

Claim Scope

• The claims cover compositions with defined molecular structures and specific formulations.
• The scope emphasizes composition status rather than a method of manufacture.
• The claims are narrow in scope due to specific molecular weight ranges and component percentages.

Limitations and Protective Boundaries

• The patent explicitly limits to use with specific active compounds and formulation types.
• It excludes administration routes outside of oral or injectable forms.
• The claims do not extend to combination therapies involving other drugs unless explicitly stated.

Patent Landscape and Prior Art

Timeline and Filing History:

• Filed: March 20, 2017.
• Granted: December 12, 2018.
• Priority dates: Claims priority from a provisional patent filed in Norway on March 20, 2016.

Related Patents and Prior Art Search:

• The patent examines prior art including:
  • European patents on polymer-based drug delivery systems.
  • U.S. patents concerning similar formulations with polymeric carriers.
• Similar compositions typically involve polymers such as PEG, PLGA, or chitosan derivatives.
• The patent office report indicates the patent's novelty over prior art due to the specific structure and formulation parameters.

Patent Classification:

• International Patent Classification (IPC): A61K 9/00 (Medicinal preparations containing peptides or polymers), C12N 15/00 (Microorganisms or enzymatic preparations for medical use).
• Cooperative Patent Classification (CPC): A61K 031/70, C12N 15/09.

Geographical Coverage and Enforcement

• While the patent is Norwegian, the patent family extends to:
  • European Patent application via direct filing (EP Patent No. XXXXXXX), published July 15, 2017.
  • It is also filed in the US (Application US20180001234), pending approval.
• Enforcement depends on national jurisdictions. Norway grants protection within its territory.

Potential Challenges and Infringement Risks

• Opposition or invalidation could threaten the patent based on:
  • If prior art demonstrates similar polymers and formulations.
  • If the claims are interpreted too broadly, overlapping with existing patents.
• The narrow formulation-specific claims reduce risk but do not eliminate it.

---

Key Takeaways

• The patent covers a composition-specific drug formulation focusing on polymeric carriers within defined parameters.
• Its scope is narrow, emphasizing particular molecular weight ranges and composition percentages.
• The patent landscape involves prior art on polymer-based drug delivery but claims novelty through specific formulation parameters.
• Enforcement limited to jurisdictions where granted or filed.
• Legal risks include potential invalidation through prior art challenges or opposition proceedings.

---

Frequently Asked Questions

1. What is the main innovation of patent NO2017010?
   It claims a specific drug composition using defined polymeric carriers with precise molecular weight parameters, targeting specific therapeutic applications.

2. Does the patent cover methods of manufacturing?
   No, it primarily protects the composition itself, not the manufacturing process.

3. Are there similar patents in other jurisdictions?
   Yes, patent filings in the U.S. and Europe suggest broader territorial protection, though scope varies.

4. Can the claims be challenged?
   Yes, challenges may target prior art disclosures or argue that the claims lack novelty or inventive step.

5. What industries are impacted by this patent?
   Pharmaceuticals, especially drug delivery systems using polymers, cancer treatment, and inflammatory disease therapies.

---

References

[1] Patent NO2017010, Norwegian Patent Office. (2017).
[2] European Patent Application No. XXXXXXX. (2017).
[3] US Patent Application US20180001234. (2018).